DECEMBER 4, 2023

Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure Biophytis announces the signing of a new partnership with the University of Liège to carry out a range of preclinical research projects, particularly in the treatment of respiratory failure caused by the flu virus Influenza. Under this partnership, the University’s animal pathology research laboratory, headed by Professor Daniel Desmecht, will conduct a series of experiments aimed at establishing the therapeutic potential of Sarconeos (BIO101) in an experimental murine model of infection by an Influenza A virus, which could cause respiratory failure

Lire le communiqué de presse »

NOVEMBER 27, 2023

Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board Biophytis announced the appointment of Dr Yann Meunier and Professor Bernard Lévy to its Scientific Advisory Board. Yann Meunier is a US-based healthcare professional, currently Professor and Director of the International Institute of Medicine and Science, Inc (IIMS), where he leads the development and implementation of innovative educational programmes and research projects in global health and related fields. He is also a consultant and health expert with HealthConnect International LLC. Over the course of his career, he has worked with leading organisations such as Stanford Hospital & Clinics,

Lire le communiqué de presse »

NOVEMBER 20, 2023

Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million Biophytis announces the successful completion of its capital increase with shareholders’ pre-emptive subscription rights (DPS) through the issue of shares with redeemable share warrants (ABSAR), for an amount, including issue premium, of approximately €1.96 million (the “Capital Increase”). Stanislas Veillet, Co-founder, and CEO of Biophytis, said: “I would like to thank all the shareholders and investors who have contributed to the success of this capital increase and expressed their confidence in our strategy. This operation will help to finance the next major steps in

Lire le communiqué de presse »

NOVEMBER 06, 2023

Biophytis to attend BIO-Europe in Munich Biophytis announces that the company is attending the BIO-Europe conference which will be held in Munich, Germany, November 6th to 8th 2023. The conference will, as every year, bring together all the players in the pharmaceutical and biotech industries. As part of the international development strategy for Sarconeos (BIO101) in the treatment of severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy, Edouard Bieth, Chief Business Officer of Biophytis, will meet pharmaceutical industry decision-makers to initiate co-development and commercialization partnerships for the company’s drug candidate. Securing an R&D and commercialization partnership agreement is a

Lire le communiqué de presse »

OCTOBER 30, 2023

Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (BIO101) in Brazil Biophytis announces the signature of a partnership with Innovation Solutions Pharma, a company specializing in support for clinical development and drug registration operations in South America, with a view to accelerate market access for Sarconeos (BIO101) in Brazil. As part of this partnership, Innovative Solutions Pharma will represent Biophytis in front of the Brazilian agency ANVISA to lift the suspension of the Early Access Program (EAP) authorized at the beginning of 2022. This program will enable a maximum of 80 patients suffering

Lire le communiqué de presse »

OCTOBER 27, 2023

Biophytis receives notice of delisting from Nasdaq and announces it will request a hearing before the Nasdaq Hearings Panel Biophytis announces that it has received a notice of delisting from Nasdaq. The staff of the Listing Qualifications Department has determined that the Company’s securities have not regained compliance with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(b). The Notice further states that unless the Company timely requests a hearing before a Nasdaq Hearings Panel, the Company’s securities would be subject to delisting. Accordingly, the Company intends to

Lire le communiqué de presse »

OCTOBER 23, 2023

Biophytis announces the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap Public offering of ABSARs: new shares with redeemable share subscription warrants (BSARs) Subscription price: €0.0093 per new share each with a subscription warrant Subscription ratio: 3 ABSARs for 8 existing shares Trading period for the preferential subscription rights: from October 26, 2023 to November 9, 2023 inclusive Subscription period: from October 30, 2023 to November 13, 2023 inclusive Subscription commitments: €1,960,000 or 75% of the issue   Biophytis is announcing the terms of a rights issue set

Lire le communiqué de presse »

SEPTEMBER 25, 2023

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101) Biophytis and Skyepharma, a French pharmaceutical company specializing in the formulation, development and production of pharmaceutical products, announce the signature of a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19, with a view to the submission of marketing authorization applications. Based on the active ingredient produced by SEQENS, Skyepharma will develop finished product batches meeting the GMP (Good Manufacturing Practice) standards required for market access filings. The key stages in the production of Sarconeos (BIO101) will be entrusted to

Lire le communiqué de presse »

SEPTEMBER 19, 2023

Biophytis provides an update on its early access programs for Sarconeos (BIO101) in the treatment of severe forms of COVID-19 Biophytis announced that it has received a response from the French National Authority for Health (HAS) to its request for Early Access Authorization in France for patients suffering from severe forms of COVID-19 and provides an update on its strategy in other countries. After examining the Early Access Authorization request file submitted at the end of May 2023, HAS considered that the Company had not provided sufficient data allowing it to evaluate precisely the benefit vs. risk ratio and to

Lire le communiqué de presse »